> Contact us

Watch video

IMPLEMENTING REAL-TIME MONITORING AND MAKING IT A SUCCESS STORY

There are several success stories on how real-time monitoring has saved high value products and ensured drug availability. However, Niclas Ohlsson, CEO at TSS, believes companies need to carefully assess and plan before deciding to implement real-time monitoring in their life science supply chains.

Scroll to read on 

I

In the TSS real-time application you can follow your most valuable shipments live, all the way to the last mile. Although this type of application opens up for huge possibilities, it is important to remember that it also requires companies to think through how the organisation and its processes are affected.


This typically calls for an escalation process as well as an organization that is available 24/7, with a global operation team that can, if needed, interact and initiate corrective actions. In the complex eco system of a supply chain, that may involve different companies, experts need to be accessible and actionable.

The first impact of implementing real-time monitoring is the need for a control tower. This control tower must be able to capture all alarms, to be qualified to interpret them, and to conclude what action is suitable, and by whom

Before deciding to implement real-time monitoring, you need to ask yourself: is there a risk that we turn our organization into a reactive rather than a proactive organization? And what is the cost for that?

Niclas Ohlsson says, that, in order to assess the possible effectiveness of real-time monitoring, the supply chain’s white and dark spaces need to be identified. Depending on how your supply chain has been set up, it is important to map areas where possible actions can be taken, but also where it can not be. This information should be mapped against historical data where issues are typically initiated or escalating.


“If there is a high positive overlap, the analysis should assess the causes for the deviation. Knowing this, you need to assess how such a situation can be addressed in the field - which action is required?”


The percentage of cases that could be addressed, and the cost for these real time actions, should then be compared with a proactive action that could alternatively resolve the issue.

To make sure your real-time monitoring experience becomes a success stories, it is crucial that you know which questions to ask during the evaluation process, and what to expect from the vendor. 

> Download TSS’ buyer’s guide to real-time temperature monitoring to learn more!

Go to article: Home | The Dawn of Big DataGo to article: EditorialGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: How will Amazon's acquisition of online pharmacy business PillPack disrupt the pharmaceutical industry? Go to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Fentanyl: where did it all go wrong?Go to article: NSFGo to article: Komtur Pharmaceuticals Company InsightGo to article: Komtur PharmaceuticalsGo to article: Turning up the heat on nano researchGo to article: TSS Company InsightGo to article: TSS ABGo to article: MedelpharmGo to article: Cracking the mystery of Alzheimer's diseaseGo to article: Röchling Medical NeuhausGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: Where are the world's pharma manufacturing hotspots?Go to article: Gerteis Company InsightGo to article: GerteisGo to article: ZenatekGo to article: How India’s use of unapproved antibiotics could undermine global healthGo to article: Novo Nordisk PharmatechGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: CRISPR: a seismic shift in gene editingGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: Is the UK’s drug evaluation system in need of an overhaul?Go to article: Nelson Labs Company InsightGo to article: Nelson LabsGo to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: Opening up the Chinese drug marketGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Immunising against opioids – could a vaccine solve the crisis? Go to article: Molnar Company InsightGo to article: MolnarGo to article: PharmasolGo to article: The next generation of antimalarials Go to article: Oncology Therapeutic Development Company InsightGo to article: Oncology Therapeutic DevelopmentGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: The People vs Big Pharma: tackling the industry’s trust issuesGo to article: G.F.Go to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Amazon and PillPack: an unstoppable pharmacy force?Go to article: BEAGo to article: Buchi Labortechnik AG Company InsightGo to article: Buchi Labortechnik AGGo to article: Is the microbiome as important for precision medicine as genetics?Go to article: Medical HempGo to article: Senn ChemicalsGo to article: Senn ChemicalsGo to article: Niconex Medical LtdGo to article: HPV vaccines: a decade of progressGo to article: Med-Script AssociatesGo to article: B&W Tek | Company InsightGo to article: B&W TekGo to article: EventsGo to article: CG ChemikalienGo to article: AlpexGo to article: Next issueGo to article: Pall Biotech Company InsightGo to article: CrewpharmGo to article: EndocaGo to article: Diversey